A systematic review of preclinical studies on the efficacy of propolis for the treatment of inflammatory bowel disease

Soleimani, D. and Miryan, M. and Tutunchi, H. and Navashenaq, J. G. and Sadeghi, E. and Ghayour-Mobarhan, M. and Ferns, G. A. and Ostadrahimi, A.

Phytotherapy Research (2020) 35: 701–710

DOI: 10.1002/ptr.6856

Abstract

Propolis is a resinous substance produced by bees from plants. There has been some evidence indicating that propolis may be a candidate for the treatment of inflammatory bowel disease (IBD) because of its potent antioxidant properties and ability to modulate immune response and gut microbiome. The objective of this systematic review was to investigate the role of propolis in the treatment of IBD, emphasizing possible mechanisms underlying the anti-inflammatory properties of it. Searches were performed in ISI, PubMed/Medline, Scopus, EMBASE, and Cochrane Library databases up to March 2020. According to the studies examined in this review, the administration of propolis can be useful in attenuating many aspects of clinical, macroscopic, and histological features of colitis in animal models. The efficacy of propolis in the treatment of IBD might be attributed to its potent antioxidants and anti-inflammatory activities. Propolis may also be involved in the modulation of the gut microbiota and in the improvement of the intestinal mucosal barrier function. The major mechanism of action is most likely to be mediated via the prevention of some transcriptional factors and associated proteins. However, future studies are warranted to investigate the clinical utility of propolis as a candidate in the treatment of IBD.

Citation

Soleimani, D., Miryan, M., Tutunchi, H., Navashenaq, J. G., Sadeghi, E., Ghayour-Mobarhan, M., Ferns, G. A., & Ostadrahimi, A. (2020). A systematic review of preclinical studies on the efficacy of propolis for the treatment of inflammatory bowel disease. Phytotherapy Research, 35(2), 701–710. https://doi.org/10.1002/ptr.6856 inflammation, animal models, systematic reviews, intestines, Non-food/Non-feed Animal Products [SS100], laboratory animals, antiinflammatory properties, disease models, efficacy, Non-communicable Human Diseases and Injuries [VV600], Animal Models of Human Diseases [VV400], anti-inflammatory properties, colitis, digestive tract mucosa, enteropathy, hive products, inflammatory bowel diseases, intestinal diseases, mucosa, mucous membrane, propolis, transcription factors

Keywords

• inflammation
• animal models
• systematic reviews
• intestines
• Non-food/Non-feed Animal Products [SS100]
• laboratory animals
• antiinflammatory properties
• disease models
• efficacy
• Non-communicable Human Diseases and Injuries [VV600]
• Animal Models of Human Diseases [VV400]
• anti-inflammatory properties
• colitis
• digestive tract mucosa
• enteropathy
• hive products
• inflammatory bowel diseases
• intestinal diseases
• mucosa
• mucous membrane
• propolis
• transcription factors